Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06773910 · ClinicalTrials.gov registry record · Phase 2
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
A Phase 2 study of Limited Stage Small Cell Lung Cancer, sponsored by SCRI Development Innovations.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06773910: Recruiting Phase 2 study of Limited Stage Small Cell Lung Cancer, sponsored by SCRI Development Innovations.
NCT06773910 is a Phase 2 study of Limited Stage Small Cell Lung Cancer that is actively recruiting participants, run by SCRI Development Innovations. The registered enrollment target is 250 participants, roughly in line with the 257-participant average among 4 other Limited Stage Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06773910, a Phase 2 study of Limited Stage Small Cell Lung Cancer, is actively recruiting participants, sponsored by SCRI Development Innovations.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Primary Outcome
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG BMS-986489
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- University of Miami - Sylvester Cancer Center - Miami
- Ocala Oncology Center - Ocala
- Florida Cancer Specialists - North - Orange City
- Cancer Care Centers of Brevard - Palm Bay
- Florida Cancer Specialists - East - West Palm Beach
Illinois
- Illinois Cancer Specialists - Arlington Heights
- Illinois Cancer Care - Peoria
Kentucky
- Baptist Health - Lexington - Lexington
- Baptist Health - Louisville - Louisville
Ohio
- Oncology Hematology Care - Cincinnati
- Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center - Columbus
Alabama
- Southern Cancer Center - Daphne
California
- Sansum Clinic - Santa Barbara
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Minnesota
- Minnesota Oncology Hematology - Maple Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2032-09 |
| Phase | Phase 2 |
What NCT06773910 shows while recruiting
NCT06773910 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 257-participant average among 4 other Limited Stage Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 1 condition, with Limited Stage Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT06773910 names 20 study sites across 12 states, led by Florida, Illinois, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06773910 about?
NCT06773910 is a clinical study titled "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)". This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profi...
What is the current status of trial NCT06773910?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-03-11. Estimated completion is 2032-09.
What conditions does trial NCT06773910 study?
This clinical trial studies the following conditions: Limited Stage Small Cell Lung Cancer.
What interventions are being tested in trial NCT06773910?
The interventions under investigation include: Durvalumab (DRUG), BMS-986489 (DRUG).
Who is sponsoring clinical trial NCT06773910?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06773910 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Limited Stage Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
COMPLETED · Phase 2
-
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
COMPLETED · Phase 2
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI